The Phase 1b MUIR data shows azenosertib + paclitaxel meaningfully improves ORR and PFS vs. historical paclitaxel monotherapy benchmarks in heavily pre-treated PROC. The 250 mg intermittent dose suggests manageable safety. With the company's core registration strategy in Cyclin E1-positive monotherapy, this combination proof-of-concept expands the total addressable market. Expect stock volatility around the ASCO presentation on June 1, but given the early-phase nature and small sample sizes, the filing alone is a moderate positive catalyst, not a transformational event.
Price Chart
Executive Summary
Zentalis Pharmaceuticals announced Phase 1b MUIR trial data for azenosertib plus paclitaxel in platinum-resistant ovarian cancer (PROC), showing a 39.1% ORR and 7.3-month median PFS across all cohorts (n=46), with a 50% ORR and 9.2-month median DOR at the 250 mg intermittent dose (n=12). The data will be presented at ASCO 2026. As a pre-revenue biotech with a $264M market cap, the filing is noteworthy for pipeline progress but does not change the risk profile.
Key Facts
- ORR of 39.1% across all four dose cohorts (n=46) in PROC patients, vs. historical paclitaxel monotherapy ORR of ~30%.
- At the 250 mg intermittent dose (n=12), ORR was 50.0% including one complete response, with a median DOR of 9.2 months.
- Median PFS of 7.3 months across all cohorts vs. historical paclitaxel monotherapy median PFS of ~4 months.
- One Grade 5 event (sepsis) previously reported in June 2024, assessed as related to azenosertib by investigator.
- Data will be presented at ASCO 2026 (June 1, 2026).
Financial Impact
No financial data in filing; clinical data supports potential expansion of azenosertib label into combination settings, which could increase peak revenue opportunity if approved.
Risk Factors
- Small Phase 1b sample (n=46) — data may not replicate in larger randomized trials.
- Grade 5 event (sepsis) attributed to azenosertib remains a safety concern.
- No financial data filed — company has significant cash burn with no approved products.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000045 |
| Document: asco2026datapressreleasefi.htm | 0001725160-26-000045 |
| Document: 0001725160-26-000045-index-headers.html | 0001725160-26-000045 |
| Document: 0001725160-26-000045-index.html | 0001725160-26-000045 |
| Document: 0001725160-26-000045.txt | 0001725160-26-000045 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.52 (+31.98%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.52 (+29.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.52 (−32.80%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.52 (−36.20%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.52 (−36.84%) |
Apr 17, 2026 24w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.52 (−45.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access